Full Text
Abstract
Introduction. The close interrelation between cancer and thromboses is well proven on today. However usual screening tests are not sensitive to hypercoagulation that limits their use to predict tromboembolic complications.
Aim: to study coagulative hemostasis in patients with non-Hodgkin’s lymphomas (NHL) using screening and integral tests in order for their comparison.
Materials and methods. We examined 75 patients with first-identified B-cell NHL (40 with aggressive and 35 with indolent lymphomas). Blood coagulation was examined before specific antitumor therapy and after 4–6 courses of polyсhemotherapy using coagulogram and «Тhrombodynamics» test.
Results. In the diagnosis of disease the significant increasing of initial clot growth rate (Vi), stationary clot growth rate (Vs) and clot size (Cs) were determined. At early stages of disease 26 patients had increased Vs and Cs. 49 patients with generalized stages of NHL had increased Vi, Vs, Cs, prothrombin time by Quick (PT), thrombin time, level of soluble fibrin-monomer com- plexes, shortening of activated partial thrombin time (APTT); in 27 of them (55%) growth of spontaneous clot away from the ac- tivator was observed. Analysis of procoagulant activity in patients with generalized stages of disease revealed a significant in- creasing of Cs, PT and shortening of APTT. In 34 (45%) NHL-patients with remission the tendency to hypercoagulation remained.
Conclusion. The results obtained indicate a high sensitivity of «Тhrombodynamics» test to procoagulant conditions in pa- tients with NHL.
REFERENCES
1. Boillaud J. B. De la obliteration des veines et de son influence sur la formation des hidropisies partielles: consideration sur la hydropi- sies passive et general. Arch Gen Med. 1823; 1: 188–204.
2. Trousseau A. Phlegmasia Alba Dolens. In: Clinique Medicale de 1’Hotel Dieu de Paris [Ed. J. B. Balliere]. 2nd ed. Paris, Balliere. 1865; 3: 654–712.
3. Petrova O. Yu., Suhanov VA, Levit D. A. Hypofibrinolysis as the main risk factor for thromboembolic complications in cancer patients. [Gipofibrinoliz kak osnovnoj faktor riska tromboemboli- cheskih oslozhnenij u onkologicheskih pacientov]. Zlokachestven- nye opuholi. 2014; 3: 147–54 (in Russ.).
4. Virchov R. Neuer Fall von todlicher Emboli der Lungenarterie. Arch Pathol Anat. 1856; 10: 225–8.
5. Boral B. M., Williams D. J., Boral L. I. Disseminated Intravascular Coagulation. J Clin Pathol. 2016; 146 (6): 670–80.
6. Hillen H. F. Thrombosis in cancer patients. Ann Oncol. 2000; 11 (3): 273–6.
7. Buryakovskaya L. I., Sumarokov A. B., Uchitel I. A., Gupa- lo E. M. Anti-inflammatory effect of clopidogrel in atherosclero- sis. [Protivovospalitel’noe dejstvie klopidogrela pri aterosklero- ze]. Racional’naya farmakoterapiya v kardiologii. 2011; 7 (6): 677– 84 (in Russ.).
8. Colman R. W., Schmaier A. H. Contact system: a vascular biol- ogy modulator with anticoagulant, profibrinolytic antiadhesive and proinflommatory attributes. Blood. 1997; 90 (10): 3819–43.
9. Handbook of venous disorders: Guedelines of the American Venous Forum [Ed. P. Glowiczki]. 3rd ed. London, UK: Hodder Arnold. 2009: 744 p.
10. Strukova S. Blood coagulation-dependent inflammation, and inflammation — dependent thrombosis. Front Biosci. 2006; 11 (1): 59–80.
11. Loreto M. F., Martinis D. E., Corsi M. P. Coagulation and cancer: implications for diagnosis and management. Pathol Oncol Res. 2000; 6 (4): 302–12.
12. Falanga A., Gordon S. G. Isolation and characterization of cancer procoagulant: A cysteine proteinase from malignant tissue. Bio- chemistry. 1985; 24 (20): 5558–67.
13. Rubin O., Crettaz D., Tissot J. D. et al. Microparticles in stored red blood cells: submicron clotting bombs? Blood Transfus. 2010; 8 (3): 31–8.
14. Nabiullina R. M. Mechanisms of blood microvesicles influence on the formation, structure and stability of the fibrin clot. [Mekha- nizmy vliyaniya mikrovezikul krovi na formirovanie, strukturu i ustojchivost’ fibrinovogo sgustka]. Avtoref. dis. kand. med. nauk. Kazan’. 2015: 22 s (in Russ.).
15. Suhareva E. G. Influence of erythrocyte microvesicles on hemo- stasis in norm and pathology (on the model of thermal trauma). [Vliyanie eritrocitarnyh mikrovezikul na gemostaz v norme i pri patologii (na modeli termicheskoj travmy)]. Avtoref. dis. kand. biol. nauk. Moskva. 2016: 30 s (in Russ.).
16. De Luca L., D’Arena G., Simeon V. et al. Characterization and prog- nostic relevance of circulating microvesicles in chronic lympho- cytic leukemia. Leukem Lymph. 2017; 58 (6): 1424–32.
17. Runyi Ye., Caisheng Ye., Yongbo H. et al. Circulating tissue fac- tor positive microparticles in patients with acute recurrent deep venous thrombosis. Thromb Res. 2012; 130 (2): 253–8.
18. Cockrell E., Espinola R., McCrae K. Microparticles as a predictor of acute deep venous thrombosis in a patient with Antiphospho- lipid Antibody Syndrome. 49th Annual Meeting of the American- Society-of-Hematology. Blood. 2007; 110 (11): 64B.
19. Kleinjan A., van Doormaal F. F., Berckmans R. J. et al. Measure- ment of procoagulant activity of microparticles by the fibrin gen- eration test as a predictor for venous thrombosis in cancer patients. 2010; 4. URL: www. rug. nl/research/portal/publications/measure- ment-of-procoagulant-activity-of-microparticles-by-the-fibrin- generation-test-as-a-predictor-for-venous-thrombosis-in-can- cer-patients(f47f4451–1217–4bef-a0c3-b36b4654d88a). html. [Accessed 13.05.2018].
20. Satish М., Chang S., Seegobin K. Increased risk of arterial throm- boembolic events with combination lenalidomide/dexametha- sone therapy for multiple myeloma. Expert Rev Anticancer Ther. 2017; 17 (7): 585–91.
21. De Stefano V., Sora F., Rossi E. et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagno- sis and during treatment. J Thromb Haemost. 2005; 3 (9): 1985–92.
22. Lee K. R., Subrayan V., Win M. M. ATRA-induced cerebral sinus thrombosis. J Thromb Thrombolys. 2014; 38 (1): 87–9.
23. Mendeleeva L. P., Votyakova O. M., Pokrovskaya O. S. et al. Nation- al clinical recommendations for the diagnosis and treatment of multiple myeloma. [Nacional’nye klinicheskie rekomendacii po diagnostike i lecheniyu mnozhestvennoj mielomy]. Gematologiya i transfuziologiya. 2016; 61 (1, pril. 2): 1–24 (in Russ.).